Timothy Thullen

Timothy Thullen, PhD, DABT has over twenty years of work experience in the field of toxicology. Timothy began their career in 1996 as a Howard Hughes Summer Intern at Miami University. In 1997, they became a PhD Student at the University of Cincinnati College of Medicine, where they conducted research on host/pathogen interaction of Pneumocystis and developed a new rat model of Pneumocystis. In 2003, they became a Post-Doctoral Fellow at The Jackson Laboratory. In 2005, they became a Staff Toxicologist at WIL Research Laboratories, LLC, where they were responsible for the planning, conduct and successful reporting of developmental, reproductive and neurotoxicity studies. In 2009, they became a Senior Scientist at Vertex Pharmaceuticals, where they were the primary scientist on numerous projects for several indications, including two cancer programs, influenza, sepsis, tuberculosis, MRSA, and respiratory syncytial viral infection. In 2013, they became a Principal Scientist and Senior Scientist, Toxicology, Preclinical Safety at Biogen, where they were the primary scientist on projects for ALS, Alzheimer's, Multiple Sclerosis, Neuropathic Pain, Schizophrenia, Spinal muscular atrophy, Stroke, and Systemic Lupus Erythematosus. In 2019, they became the Director of DMPK and Toxicology and Director, Toxicology at Corbus Pharmaceuticals. In 2020, they became the Director of Toxicology at X4 Pharmaceuticals. In 2021, they became the Director of Regulatory Toxicology at Wave Life Sciences and the Executive Director of Nonclinical Development at Third Harmonic Bio.

Timothy Thullen, PhD, DABT obtained their BA in Biology from Hiram College in 1997. Timothy then completed a summer research project in Microbiology at Miami University in 1996. In 2003, they earned their PhD in Pathobiology and Molecular Medicine from the University of Cincinnati College of Medicine. Timothy was awarded Diplomate of the American Board of Toxicology from the American Board of Toxicology in 2009, and was granted DABT from the American Board of Toxicology, Inc. in 2020.